Novel strategies to overcome resistance to endocrine therapy are on the horizon, especially PI3K inhibitors, CDK 4/6 inhibitors, and agents targeting methylation. However, many, if not most, patients with progressive estrogen receptor-positive breast cancer will continue to show response to multiples lines of endocrine therapy alone. Which patient subsets will be candidates for the emerging agents is still unclear, but in the future, subtype of the tumor, mutational status, and treatment goals will be part of the equation. Always, it will be necessary to individualize treatment.
Copyright © 2015 by the National Comprehensive Cancer Network.